CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 48 enrolled
Drug / intervention
DaxibotulinumtoxinA for injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04259086
NCT04259086Phase 2Completed
CompareCT.gov

A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection (DAXI for Injection) for the Combined Treatment of Upper Facial Lines (Glabellar Lines, Dynamic Forehead Lines and Lateral Canthal Lines)

Revance Therapeutics, Inc.·interventional·Posted Feb 6, 2020·Updated Jun 27, 2023

In Brief

A Phase 2 clinical trial evaluating DaxibotulinumtoxinA for injection for Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines). Completed, enrolled 48 participants across 8 sites in 2 countries.

Detailed Summary

This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of DaxibotulinumtoxinA for injection (DAXI for injection) in the treatment of Glabellar Lines (GL), Dynamic Forehead Lines (FHL), and Lateral Canthal Lines(LCL)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUpper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedFeb 6, 2020
Enrollment StartDec 6, 2019
Primary CompletionNov 2, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.4 years ago

Interventions

DaxibotulinumtoxinA for injectiondrug

Intramuscular injection